DYNC1LI1 Knockout 786-O Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional dissection of cytoplasmic dynein light intermediate chain 1 (DYNC1LI1) in a VHL-deficient renal carcinoma background. This product consists of a heterogeneous pool of 786-O cells carrying targeted disruption of the DYNC1LI1 gene, enabling loss-of-function studies without clonal selection artifacts. The polyclonal format preserves population-level diversity and is well-suited for experiments requiring moderate to high knockout efficiency across a cell pool, including autophagy flux assays, immunolocalization, and drug sensitivity profiling. As a gene-edited derivative of the widely used 786-O cell line, this model offers a physiologically relevant context for investigating dynein-dependent processes in hypoxia-driven tumorigenesis.
The parental 786-O cell line is a human clear cell renal carcinoma epithelial line that lacks functional von Hippel-Lindau (VHL) tumor suppressor, leading to constitutive stabilization of hypoxia-inducible factors (HIFs) even under normoxic conditions. This VHL-null background drives a pseudo-hypoxic state characterized by upregulation of angiogenic factors, metabolic reprogramming, and altered stress responses. 786-O cells are a well-established model for studying renal cell carcinoma biology, hypoxia signaling networks, and the cellular consequences of sustained HIF activation. Their adherent epithelial morphology and robust in vitro growth make them amenable to a wide range of cell-based assays, while their defined genetic lesion in the VHL pathway ensures reproducible signaling readouts relevant to tumor adaptation.
DYNC1LI1 encodes the light intermediate chain of cytoplasmic dynein, an essential component of the minus-end-directed microtubule motor complex. It functions as part of the dynein holoenzyme, interacting directly with the dynein heavy chain (DYNC1H1) and accessory factors such as dynactin, BICD2, NDE1/NDEL1, and LIS1 to coordinate cargo binding and motor processivity. DYNC1LI1 is regulated by mTOR signaling, HIF-1??, and cell cycle kinases including CDK1, and under nutrient stress conditions it participates in autophagy initiation and autophagosome-lysosome fusion. It acts downstream of these signals to control retrograde transport of endosomes, autophagic vacuoles, and mitotic checkpoint proteins, and it is critical for Golgi positioning and mitotic spindle assembly. The dynein-dynactin complex, together with Rab7, Hook proteins, and FIP200, represents a representative pathway hub that integrates nutrient and stress cues with intracellular trafficking.
Knockout of DYNC1LI1 in the VHL-deficient 786-O background disrupts dynein-mediated retrograde transport, leading to impaired autophagic degradation and defective mitotic progression. This loss-of-function model is predicted to exacerbate HIF-1?? accumulation by compromising autophagic turnover of HIF subunits or their negative regulators, thereby altering hypoxia adaptation pathways. The interplay between dynein-dependent trafficking and the already activated hypoxic signaling axis makes this model particularly relevant for deciphering how microtubule-based transport influences tumor cell survival under metabolic stress. Researchers can use these cells to assess whether DYNC1LI1 ablation sensitizes 786-O cells to mTOR inhibitors, autophagy modulators, or chemotherapeutic agents, and to determine the contribution of dynein dysfunction to renal carcinoma progression.
Typical applications include autophagy flux analysis by monitoring LC3-II turnover in the presence of lysosomal inhibitors, immunofluorescence staining to evaluate dynein localization and Golgi integrity, cell cycle analysis to quantify mitotic delays, and Western blotting for HIF-1?? protein levels. This product also supports co-immunoprecipitation studies to probe dynein complex assembly and interactome changes upon nutrient starvation or pharmacological challenge. The polyclonal knockout cells are a valuable tool for investigating ciliopathy-related transport defects, neurodegeneration mechanisms, and renal cancer drug screening. For further information or to discuss custom modifications, please contact Ascent Research.
